← Evidence map

ArticleCancer research2026

Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

Melissa R Junttila et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

6 papers cite it

2026

this papercites it

Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations. | OpenQuestion